We develop a new generation of off-the-shelf immune cell therapies for solid tumor patients. We have established a novel allogeneic platform to enable efficacy-enhanced off-the-shelf treatment options with the potential to disrupt the market for solid tumor therapies. We recently received an investment term sheet from a syndicate of recognized VCs. The round is now quickly filling up and we would like to invite you to explore the opportunity of joining this round as an investor.